Expertise in
4
conditions

Georg R. Hess

Mainz, RP, DE 
Expertise in
4
conditions
Mainz, RP, DE 

Overview

Georg Hess practices practicing medicine in Mainz, Germany.

Mr. Hess is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Mainz, RP, Germany
Other Locations
Gutenberg, RP, Germany
Grenzach-wyhlen, BW, Germany
Wuerzburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drug: Obinutuzumab
Study Phase: Phase 2
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

98 Total Publications

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026

Frequently Asked Questions about Georg R. Hess

Is Georg R. Hess a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Georg R. Hess is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Georg R. Hess participate in research or clinical trials?

Yes. Georg R. Hess has published 98 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Georg R. Hess's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hess's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile